Citation Impact
Citing Papers
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2015
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma
2013
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
2011
Cardiovascular Implications of Diabetes, Metabolic Syndrome, Thyroid Disease, and Cardio-Oncology in Women
2018
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Hydatid Disease from Head to Toe
2003
Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis
2016 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Endpoints in cancer clinical trials
2014
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
2013
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
2015
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Renal cell carcinoma
2017 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
2015
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Systemic Therapy for Metastatic Renal-Cell Carcinoma
2017
Cellular senescence: from physiology to pathology
2014 Standout
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research
2020 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
2017 StandoutNobel
A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery
2019 Standout
Symptom Burden, Survival and Palliative Care in Advanced Soft Tissue Sarcoma
2011
Prevention and control of cystic echinococcosis
2007 Standout
Works of M. Ouali being referenced
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma
2011
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)
2015
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years
2010
Is TOMPOOL (gated blood-pool SPECT processing software) accurate to diagnose right and left ventricular dysfunction in a clinical setting?
2014
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
2011
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
2013
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials
2012
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
2009
[Hydatid cyst of the pancreas. Apropos of 7 cases].
1994
PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072).
2011
PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.
2012